Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program

OBJECTIVES: To evaluate the inhibition of progression of structural joint damage through week 48 in patients with moderately to severely active RA receiving upadacitinib as monotherapy or in combination with MTX. METHODS: Radiographic progression was assessed in two phase 3 randomized controlled tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Peterfy, Charles G, Strand, Vibeke, Friedman, Alan, Hall, Stephen, Mysler, Eduardo, Durez, Patrick, Baraliakos, Xenofon, Enejosa, Jeffrey V, Shaw, Tim, Li, Yihan, Chen, Su, Song, In-Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9348768/
https://www.ncbi.nlm.nih.gov/pubmed/34897366
http://dx.doi.org/10.1093/rheumatology/keab861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9348768/
https://www.ncbi.nlm.nih.gov/pubmed/34897366
http://dx.doi.org/10.1093/rheumatology/keab861

Ejemplares similares